Clinical studies such as SOLAR-1 [74], CAPItello-291 [75], and BOLERO-2 [76] supported the FDA approval of PAM inhibitors (alpelisib, capivasertib, and everolimus) in combination with hormonal therapy for patients with ER+/HER2− breast cancer. Here, ESR1 is linked to breast cancer.